New sedative may cut delirium risk in elderly heart surgery patients

NCT ID NCT07265128

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two sedatives, remimazolam and midazolam, to see which one causes less confusion (delirium) after heart valve surgery in people aged 65 and older. Delirium affects up to 70% of older heart surgery patients and can lead to longer hospital stays and memory problems. The trial will randomly assign 300 participants to receive one of the two drugs during surgery and monitor them for four days afterward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Remimazolam (a fast-acting sedative) and midazolam (a standard sedative)
What this could lead to
If remimazolam works better, it could offer a safer sedative option for older heart surgery patients, reducing confusion and recovery time.
What could go wrong
This is a single-center trial with 300 patients, so results may not apply to all hospitals. The difference between the two drugs might be small or none.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Anaesthesiology and Pain Medicine, Yonsei University College of Medicine

    Seoul, 120-752, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.